FDA Approval for Cytokinetics' Aficamten: A Scientific Triumph, But Wall Street Remains Wary
Biotech Breakthrough: LiveNAI Stock Rockets on Game-Changing Cancer Therapy Interest
Intellia's Big Chill: Manufacturing Woes Trigger a Wave of Downgrades